Wednesday, April 13, 2011
Durect Corp., of Cupertino, Calif., said top-line results from a Phase II trial showed that Eladur (Transdur-Bupivacaine), its transdermal bupivacaine pain patch, missed the primary endpoint of demonstrating a positive treatment difference over placebo for the mean change in pain intensity scores from baseline to the mean of week 11 and week 12. Complete data analysis is ongoing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.